BEDFORD, Mass. and WARSAW, Poland, May 26 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced the commercial launch of two new imaging agents -- ProSense® 750 FAST for expanded versatility in imaging cathepsin activity, and Neutrophil Elastase™ 680 FAST, for imaging of inflammatory elastase activity associated with disease progression and therapeutic response. The launch announcements were made at the European Molecular Imaging Meeting (EMIM) 2010 in Warsaw, Poland.
New Research and Application Areas:
- Cathepsins are well known biomarkers in a range of diseases, including atherosclerosis, oncology, pulmonary pathologies, and arthritis. The new ProSense 750 FAST agent, a faster-activating, smaller molecule product complement to VisEn's ProSense imaging agent, is designed to target a broad range of cathepsins (B, K, L, S, and V) in live cell and in vivo imaging studies. With similar pan-cathepsin readout profiles but different activation kinetics and imaging time points, VisEn's ProSense and ProSense FAST enable broader study design choices in imaging these key protease families in disease progression and therapeutic response.
- Neutrophil elastase is a key protease involved in acute lung
injury, acute respiratory distress syndrome, as well as many other
inflammatory processes such as emphysema, cystic fibrosis, COPD,
wound healing, rheumatoid arthritis, and ischemia-reperfusion.
Neutrophil Elastase 680 FAST is a selective neutrophil
elastase-activatable agent designed for imaging of this serine
protease both in vitro and in vivo</